DRD3 Antagonists Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

Dopamine receptors include D1-like (D1, D5) and D2-like (D2, D3, D4) subtypes. The D3 receptor is primarily located in the brain, especially in regions like the limbic system, nucleus accumbent, and islands of Calleja, playing a role in reward, emotion, and motor function. DRD3 antagonists are a class of drugs that target the dopamine D3 receptors in the brain. These receptors are part of the dopamine system, crucial in regulating mood, behavior, and cognition. The mechanism of action involves blocking the activation of D3 receptors, leading to altered dopamine signaling. DRD3 antagonists have been investigated as potential treatments for neuropsychiatric disorders, including schizophrenia, bipolar disorder, and major depressive disorder. By modulating dopamine neurotransmission, these antagonists aim to alleviate symptoms associated with these conditions, such as psychosis, mood disturbances, and cognitive impairments. However, the development and clinical use of DRD3 antagonists are still in the early stages, and more research is needed to fully understand their therapeutic potential and determine their effectiveness and safety in treating these complex neuropsychiatric disorders. As the dopamine system and its role in mental health disorders advance, DRD3 antagonists hold promise as a targeted therapeutic approach, offering hope for improving the lives of those affected by these challenging conditions. Extensive research is being conducted to find new and novel molecules to prevent and cure these diseases. The development and launch of newer products by the market players will significantly enhance the revenue of the DRD3 Antagonists market over the forecast years.

Several of these inhibitors are in the market, while many are in ongoing clinical trials. 18 companies in their pipelines have 19 products in various stages of clinical trials. 2 products are in Phase 4, 3 products are in Phase 3, and 2 products are in Phase 2 of the clinical trials.

Approved molecules

  • Abilify Maintena (aripiprazole depot formulation)
  • Abilify MyCite (aripiprazole tablets embedded with sensor)

Drugs in Pipeline

  • Dordaviprone (ONC201)
  • Barhemsys (Intravenous Amisulpride)
  • TAK-906
  • ABT-614
  • Rotundine (Levo-Tetrahydropalmatine)
  • Mesdopetam (IRL790)
  • F17464
  • Lonasen Tape (Blonanserin Transdermal Patch)
  • N-Methyl Amisulpride (LB-102)
  • CVL-936

Clinical Activity and Developments of DRD3 Antagonists

As of July 2023, 19 products for 97 diseases are in 94 clinical trials. For instance,

  • Ospedale Maggiore Policlinico is conducting a Phase 4 trial to explore the Impact of Aripiprazole Long acting on Myelin and Cognition in the onset of Schizophrenia that was expected to complete by December 2022.
  • The University of Miami is conducting a Phase 4 trial to examine the comprehensive treatment of early-course Schizophrenia which is expected to complete by July 2025.
  • Gustave Roussy, Cancer Campus is conducting a Phase 3 clinical trial to evaluate the efficacy of ONC201 compared to everolimus for Diffuse Intrinsic Pontine Glioma (DIPG) eradication that is expected to complete by September 2031.

Molecule name

Number of studies

Abilify Maintena (aripiprazole depot formulation)


Abilify MyCite (aripiprazole tablets embedded with sensor)


dordaviprone (ONC201)


Barhemsys (intravenous amisulpride)




Target Indication Analysis of DRD3 Antagonists

DRD3 antagonists have been studied as potential therapeutic agents for various neuropsychiatric disorders. One of the primary indications where they find the most use is in schizophrenia treatment. By targeting the dopamine D3 receptors in the brain, these antagonists aim to modulate dopamine signaling, which may help alleviate the positive and negative symptoms of schizophrenia. Additionally, DRD3 antagonists have shown promise in treating substance use disorders, particularly in managing drug cravings and withdrawal symptoms. The D3 receptors' involvement in the reward pathways makes these antagonists potential candidates for reducing drug-seeking behavior and promoting abstinence. Furthermore, these drugs have been investigated for their potential in managing mood disorders, such as bipolar disorder and major depressive disorder, alcohol-related disorders, Hyperinsulinism, Type 2 Diabetes, Mood disorders, and more. Although still in the early stages of research, DRD3 antagonists hold potential as targeted therapies for these challenging neuropsychiatric conditions, offering hope for improved outcomes and better quality of life for affected individuals.

Frequently Asked Questions

Abilify Maintena (aripiprazole depot formulation) and Abilify MyCite (aripiprazole tablets embedded with sensor) are approved by the FDA.

These are being used in various indications like Schizophrenia, Mood disorders, Type 2 Diabetes, Depression and many more.

Otsuka Pharmaceuticals, Lundbeck A/S, Chimerix Inc, Eagle Pharmaceuticals and Takeda Pharmaceuticals are some of the major market players for DRD3 Antagonists.

Rising incidence of diseases improvement in technologies, development of new treatment lines in the market and changing lifestyles leading to different type of cancers like Neurological and Psychotic disorders are the key opportunities for DRD3 Antagonists in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Otsuka Pharmaceutical
  • Lundbeck A/S
  • Chimerix Inc
  • Eagle Pharmaceuticals
  • Takeda Pharmaceuticals
  • AbbVie
  • University of Maryland
  • Ipsen SA
  • Pierre Fabre
  • Nitto Denko
  • Sumitomo Pharma
  • LB Pharmaceuticals
  • Cerevel Therapeutics

Adjacent Markets